Ramy Ibrahim, M.D.
Ramy has spent more than 2 decades working at academia, major pharma companies and non-profit organizations advancing the early stages of immuno-oncology therapies. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. At BMS he was an integral member of the team that developed and ultimately achieved the regulatory approval of the first checkpoint inhibitor that paved the way for immuno-oncology to become the 4th pillar of cancer therapy. He contributed to growing the IO portfolio at AstraZeneca/Medimmune and built the clinical team that ran multiple global registrational studies with IO therapies both as single agents and in combinations. Ramy built a translational regulatory and clinical development team at the Parker Institute for Cancer Immunotherapy that worked with leading immuno-oncology scientists to develop products, INDs, and company creation. Most recently, he served as the CMO and US GM at bit.bio, a synthetic biology, clinical stage company that’s pioneering iPSCs reprogramming. Ramy serves as a board member of cell and gene therapy organizations including 2seventy bio and Parker Institute for Cancer Immunotherapy. He is a board member and the chairman of the R&D committee at Surface Oncology.